Quantifying the Burden of Type 2 (T2) Inflammation in Asthma

QUANTAS-PC: Quantifying the Burden of Type 2 (T2) Inflammation in Asthma in Primary Care and Community Specialty Practices

This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.

Participant Inclusion Criteria

• Age 18 years and older
• Ability to consent and comply with protocol assessments
• Pre-existing diagnosis of asthma and has started treatment

Participant Exclusion Criteria

• Participant deemed medically ineligible per the opinion of the investigator
• History of respiratory/lung disease other than asthma (e.g., COPD, emphysema, chronic bronchitis, tuberculosis, cystic fibrosis, lung cancer, recurrent pneumonia or other chronic lung disease)
• Participants who meet criteria for GINA 5, severe asthma (ICS + additional controllers)
• Current Enrollment in an asthma intervention trial that could affect asthma outcomes clinically and T2 biomarkers
• Visit with a specialist (i.e. Pulmonologist or Allergist) in the past year who is measuring FeNO levels